United States: XOMA Granted First European Patent Covering XOMA 052.Byline: kusumv03 XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, today announced the grant of its first European Patent related to the XOMA 052 program. Granted by the European Patent Office, the patent covers XOMA's interleukin-1 beta (IL-1 beta) antibody XOMA 052, as well as nucleic acids Nucleic acids The cellular molecules DNA and RNA that act as coded instructions for the production of proteins and are copied for transmission of inherited traits. , expression vectors and production cell lines for the manufacture of XOMA 052. The patent provides exclusivity in Europe into 2026. IL-1 beta is a pro-inflammatory cytokine Cytokine Any of a group of soluble proteins that are released by a cell to send messages which are delivered to the same cell (autocrine), an adjacent cell (paracrine), or a distant cell (endocrine). involved in the development of Type 2 diabetes type 2 diabetes n. See diabetes mellitus. , cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , rheumatoid arthritis, gout gout, condition that manifests itself as recurrent attacks of acute arthritis, which may become chronic and deforming. It results from deposits of uric acid crystals in connective tissue or joints. and other diseases. By binding to IL-1 beta, XOMA 052 inhibits the activation of the IL-1 receptor, thereby preventing the cellular signaling events that produce inflammation. Earlier this year, XOMA completed successful Phase 1 trials of XOMA 052 in Type 2 diabetes patients, and has initiated its Phase 2 clinical development program in Type 2 diabetes and cardiovascular disease. "This new patent is XOMA's first European patent providing exclusivity for XOMA 052 and complements our two U.S. Patents, which issued earlier this year," said Steven Engle, XOMA Chairman and Chief Executive Officer. Copyright : Euclid Infotech Pvt. Ltd. Provided by Syndigate.info an Albawaba.com company |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion